FDA
-
-
-
-
-
-
-
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
-
-
-
-
-
-
-
Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy
-
-
-
-
-
-
-
Cabaletta Bio Inc. (CABA) PT Lowered to $14 at Jefferies
-
-
-
-
-
-
-
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
-
-
-
-
-
-
-
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
-
-
-
-
-
-
-
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

